47
Participants
Start Date
March 26, 2018
Primary Completion Date
March 16, 2020
Study Completion Date
May 12, 2020
RPH - 104
solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
Voltaren®
Enteric-coated tablets, 25 mg and 50 mg
"Moscow City State Healthcare Institution O.M. Filatov Municipal Clinical Hospital No. 15 of the Moscow Department of Healthcare", Moscow
"State Budgetary Healthcare Institution of Moscow City Municipal Clinical Hospital No.1 named after N.I. Pirogov of Moscow Department of Healthcare", Moscow
"Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)", Moscow
"State Budgetary Healthcare Institution of Moscow City Municipal Clinical Hospital No.52 of Moscow Department of Healthcare", Moscow
"State Autonomous Healthcare Institution of the Yaroslavl Region N.V. Solovyev Clinical Emergency Hospital", Yaroslavl
"St. Petersburg State Budgetary Healthcare Institution Clinical Rheumatological Hospital No.25", Saint Petersburg
"State Budget Institution Saint Petersburg Research Insitute of emergency care named after I.I. Dzhanelidze", Saint Petersburg
"Limited Liability company Scientific Research Center Eco-safety", Saint Petersburg
"State Insitution of healthcare Tula regional clinical dermatovenerologic dispensary", Tula
"Federal State Budgetary Education Institution of Higher Education Orenburg State Medical University under Ministry of Healthcare of Russian Federation", Orenburg
"State Budgetary Institution of Healthcare of Nizhny Novgorod region City Clinical hospital #13 of Avozavodskiy district", Nizhny Novgorod
Lead Sponsor
Collaborators (3)
Covance
INDUSTRY
Unimed Laboratories
INDUSTRY
Data Matrix Solutions
OTHER
Center of Pharmaceutical Analytics LLC
INDUSTRY
OCT LLC
INDUSTRY
R-Pharm
INDUSTRY